Objectives:
Preliminary results of an impact multicenter study with a novel Scoring System (SS) based on a validated diagnostic/prognostic tool, the IQ-BTP1,2, for Breakthrough Cancer pain (BTcP) recognition and likelihood (High, Intermediate, Low). 
Methods:
The IQ-BTP SS was administered at 3 consecutive visits to over 300 cancer patients. Studied variables were: demographics, disease related information, pain therapy, Brief Pain Inventory and, physician concordance with and appreciation of the SS. We planned to establish among patients with potential BTcP the proportions of its High, Intermediate and Low likelihood and the feasibility/reliability of the SS.
Results:
The SS enabled correct classification of patients as potentially having (or not having) BTcP. In all visits ‘potential BTcP’ was found in roughly 40% of the patients. Among the latter BTcP likelihood was moderate to high in roughly 50% of cases in the first 2 visits; low BTcP likelihood was found in <20% of cases. Over 90% of participating physicians found the SS feasible and helpful in diagnosing and managing BTcP.
Conclusions:
The IQ-BTP with its SS and with adequate feasibility enables the detection of potential-BTP and its likelihood. The latter has significant relevance to BTcP epidemiology and management. 
Bibliography 
1. Samolsky Dekel BG et al. Development, validation and psychometric properties of a diagnostic/prognostic tool for breakthrough pain in mixed chronic-pain patients. Clin Neurol Neurosurg. 2016 ;141:23-9. 
2. Samolsky Dekel BG et al. Development and performance of a diagnostic/prognostic scoring system for breakthrough pain. J Pain Res. 2017;31;10:1327-1335.
Acknowledgement: 
KyowaKirin srl unconditionally supported the study

BREAKTHROUGH-PAIN LIKELIHOOD IN CANCER PATIENTS: AN IMPACT STUDY OF A NOVEL SCORING SYSTEM